Federal Grant Award Summary

Oregon Health & Science University (OHSU) received a $877,386 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 2, 2026 through May 31, 2031. The grant funds investigator-initiated research to advance HIV cure strategies by evaluating a novel triple-therapy approach combining antiretroviral therapy (ART), broadly neutralizing antibodies (bNAbs), and CCR5 (C-C chemokine receptor type 5) blockade. The primary deliverables include systematic identification of the treatment window for this triple-therapy regimen to clear the latent HIV viral reservoir in newborn macaques and determination of treatment efficacy in adult subjects infected via sexual transmission, with findings intended to establish the scientific foundation for clinical trials.

The research addresses a critical public health need by moving beyond conventional ART, which controls but does not cure HIV infection. By establishing the optimal timing and applicability of this combination approach across age groups and transmission routes, the project will generate evidence necessary to advance toward a functional HIV cure. All three therapeutic components have already entered human testing independently, positioning successful completion of this research to directly inform the transition to clinical trial evaluation of the integrated triple-therapy strategy in human subjects.